Company Profile MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young (18-40 yrs old) healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for Read more MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young (18-40 yrs old) healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy.
MacroCure currently manufactures and markets its lead product, CureXcellTM, in Israel for hard-to-heal wound treatment. The cell therapy company has its regulatory strategy in place for market approval in North America and Europe.
CureXcellTM demonstrated favorable results for standard of care (SOC) when treating various chronic wounds. Clinical trials in Israel have shown a 90% reduction of the mortality rate in patients with deep sternal wound infections and a markedly improved healing rate for severe pressure ulcers. Since the introduction of CureXcellTM to the market, more than 4,000 patients have been treated in Israel with this advanced cell therapy. No serious adverse events have been reported
| Company News
|
Executives
David, Marketing Manager
| Video
|
Products
Macrocure has developed CureXcell, a cell based therapy for hard to heal wounds, to restore the wound healing process.